DIL hits upper circuit on plan to sign term sheet to acquire stake in its subsidiary

12 Oct 2017 Evaluate

DIL is currently trading at its upper circuit limit of Rs. 1045.10, up by 49.75 points or 5.00% from its previous closing of Rs. 995.35 on the BSE.

The scrip opened at Rs. 1045.10 and has touched a high and low of Rs. 1045.10 and Rs. 1045.10 respectively.

The BSE group 'XT' stock of face value Rs. 10 has touched a 52 week high of Rs. 1070.00 on 11-Oct-2017 and a 52 week low of Rs. 590.00 on 04-Sep-2017.

Last one week high and low of the scrip stood at Rs. 1070.00 and Rs. 748.00 respectively. The current market cap of the company is Rs. 239.66 crore.

The promoters holding in the company stood at 62.59%, while institutions and non-institutions held 0.01% and 37.40% respectively.

DIL has received an approval to sign a Term Sheet to acquire 3,830,072 equity shares in its subsidiary, Fermenta Biotech (FBL), representing 21.05% of the issued and paid-up capital of FBL, from Evolvence India Life Sciences Fund LLC, a Private Equity Investor. The Board of Directors of the company at its meeting held on October 11, 2017 have authorised the same.

DIL (earlier known as Duphar-Interfran) is a well-respected public listed company. It has built a stellar reputation for itself in the arenas of pharmaceuticals, biotechnology, environmental solutions and other segments including Entertainment and Health & Wellness.

Fermenta Biotech Share Price

289.65 -0.85 (-0.29%)
24-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.50
Dr. Reddys Lab 1201.45
Cipla 1551.30
Lupin 2104.90
Zydus Lifesciences 879.85
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...